Nucleus Soft. (NUCLEUS)

FairStock Score: 25/100 — RISKY

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Nucleus Soft presents an interesting paradox. On one hand, I see a company with a sturdy balance sheet: debt-to-equity of just 0.01, a return on equity of 21.45%, and a return on capital employed of 22.60%. That's the kind of financial discipline I admire. The promoter holding at 73.60% tells me the owners are still heavily invested, aligning their interests with mine. Even the Piotroski F-Score of 7/9 suggests decent operational health. The dividend yield of 1.58% gives me some income while I wait. But the value investor in me asks: where is the growth? Sales expanded only 6.97%, and net profit grew just 0.31% in the latest year. That's hardly a compounding machine. The latest quarter shows sales of ₹220 Cr and net profit of ₹21 Cr, which if annualized is roughly in line with the flat profit growth. At a P/E of 12.92, the market isn't overpaying, but the PEG ratio of 2.44 warns me that this 'cheapness' is not cheap relative to the anaemic growth. The 52-week range—from ₹682 to ₹1,084—shows the stock has been cut in half from its high, and the FairStock Score of 38/100 echoes my mixed feelings. As Graham would say, price is what you pay, value is what you get. I'm getting decent ROE and a clean balance sheet at a reasonable price. But without a catalyst for profit acceleration, this looks like a slow grower rather than a wealth compounder. I'd need to see sustained sales momentum and margin expansion before treating it as a true Buffett-style bargain. For now, it's a watchful hold—respectable, but not exceptional.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer